{
    "id": "dbpedia_8099_2",
    "rank": 98,
    "data": {
        "url": "https://www.forbes.com/sites/russellflannery/2012/03/23/simcere-pharmaceutical-gains-3-2-after-chinas-fosun-adds-to-stake/",
        "read_more_link": "",
        "language": "en",
        "title": "Simcere Pharmaceutical Gains 3.2% After China's Fosun Adds To Stake",
        "top_image": "https://imageio.forbes.com/specials-images/imageserve/62d6b4e84973cf4561f269bb/forbes-thumb/0x0.jpg",
        "meta_img": "https://imageio.forbes.com/specials-images/imageserve/62d6b4e84973cf4561f269bb/forbes-thumb/0x0.jpg",
        "images": [
            "https://blogs-images.forbes.com/files/2014/10/Russell-Flannery_avatar_1413261162.gif"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "Business",
            "Pharma &amp; Health",
            "Chindex",
            "Fosun International",
            "Guo Guangchang",
            "Simcere"
        ],
        "tags": null,
        "authors": [
            "Russell Flannery"
        ],
        "publish_date": "2012-03-23T00:00:00",
        "summary": "",
        "meta_description": "U.S.-listed Chinese generic drug maker Simcere Pharmaceutical Group gained 3.2% yesterday on word that another Chinese pharmaceutical company has been purchasing its shares. Shanghai Fosun Pharmaceutical Group, a Shanghai-listed pharmaceutical company controlled by Chinese billionaire Guo Guangchang, said in a statement at the Shanghai Stock Exchange yesterday that a wholly owned [...]",
        "meta_lang": "en",
        "meta_favicon": "https://i.forbesimg.com/48X48-F.png",
        "meta_site_name": "Forbes",
        "canonical_link": "https://www.forbes.com/sites/russellflannery/2012/03/23/simcere-pharmaceutical-gains-3-2-after-chinas-fosun-adds-to-stake/",
        "text": "U.S.-listed Chinese generic drug maker Simcere Pharmaceutical Group gained 3.2% yesterday on word that another Chinese pharmaceutical company has been purchasing its shares.\n\nShanghai Fosun Pharmaceutical Group, a Shanghai-listed pharmaceutical company controlled by Chinese billionaire Guo Guangchang, said in a statement at the Shanghai Stock Exchange yesterday that a wholly owned subsidiary had raised its holding in Simcere to 4 million American depositary shares, representing a 7.5% stake. Shanghai Fosun Pharmaceutical had previously bought about 1% of Simcere between Dec. 13 last year and March 19, according to the statement.\n\nShanghai Fosun Pharmaceutical is 48% owned by Hong Kong-listed Fosun International, Guoâ€™s main holding company. Guo ranked No. 521 on the 2012 Forbes Billionaires List with wealth of $2.4 billion.\n\nFosun International also owns stakes in U.S.-listed Chindex, a hospital management company focused on China, and Focus Media, an outdoor advertising company headquartered in Shanghai. Fosun Media is the China licensing partner of Forbes Media.\n\n- with Maggie Chen"
    }
}